Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers. Issue 9 (1st September 2016)

• Record Type: Journal Article
• Authors: Rajan, Arun; Kim, Chul; Heery, Christopher R.; Guha, Udayan; Gulley, James L.
• Is Part Of: Human vaccines & immunotherapeutics. Volume 12:Issue 9(2016)
• Page Start: 2219
• Page End: 2231
• Publication Date: 2016-09-01
• Subjects: immunotherapy -- immune checkpoint inhibitors -- melanoma -- nivolumab -- non-small cell lung cancer -- renal cell carcinoma; Vaccines -- Periodicals; 615.372
• DOI: 10.1080/21645515.2016.1175694
• Languages: English
• ISSNs: 2164-5515

Abstract

ABSTRACT: The development of immune checkpoint inhibitors has altered the landscape of treatment of advanced cancers. These drugs are well tolerated and have shown clinical activity against a wide variety of solid tumors and hematological malignancies. The durability of response is particularly impressive when compared to other forms of systemic therapy. Nivolumab (Opdivo) is an IgG4 antibody that causes immune checkpoint blockade by diminishing inhibitory signaling through the programmed death receptor-1 pathway. It is approved for treatment of recurrent non-small cell lung cancer, melanoma, and renal cell carcinoma. Efforts to identify biomarkers of response to nivolumab are ongoing. Clinical trials are also being conducted to determine the benefits of combining nivolumab with other forms of treatment including chemotherapy, molecular-targeted therapy, radiation therapy, and other forms of immune therapy. This review outlines the clinical trials that have led to the emergence of nivolumab as a treatment option for patients with advanced cancers.